by EPHA | Dec 13, 2019 | Statements
The European Public Health Alliance has joined over 40 other organisations to call for the public interest to be protected in the EU’s new European Partnership on Innovative Health, a letter sent today to the Commissioner for Innovation, Research, Culture,...
by EPHA | Nov 21, 2019 | Statements
Establishing Treatment Optimization as part of personalised medicine development As new drugs come to the market, there is often limited knowledge on the dose, sequence, combination and duration of treatment for patients. At its 4th Access to Universal Medicines...
by European Public Health Alliance | Oct 24, 2019 | Opinion
By Ellen ‘t Hoen LLM PhD, Medicines Law & Policy Patents and other forms of exclusive rights, such as data exclusivity and market exclusivity, are meant to stimulate innovation by rewarding innovators with temporary monopolies over their innovations. These...
by European Public Health Alliance | Oct 24, 2019 | Opinion
By Charlotte Roffiaen, France Assoc Santé In France, shortages of medicines have regularly made the headlines over the past 12 months. Their numbers have indeed skyrocketed since 2008, from 44 to 868 in 2018, with a further 60% increase expected in 2019. In recent...
by European Public Health Alliance | Oct 24, 2019 | Opinion
Denis Lacombe, Director General, European Organisation for Research and Treatment of Cancer Bringing therapeutic innovation and latest science to patients while keeping patient interests at the centre is a challenging mission. Precision medicine and new approaches to...
